Skip to main content

Table 1 Characteristics of randomized controlled studies included in the meta-analysis

From: Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence

Author/year [reference]

Study design

Intervention (dose in mg)

No. of patientsa

Type of cancerb

Type of chemotherapy

Female (%)

Mean age (years)

Alcohol non-users (%)

Chemo-naive (%)

Aapro/2010 [10]

Multicenter, double-blind, non-inferiority, parallel

1) Palo (0.25) + DEX (8) on day 1

1) 151/151

Breast

AC

1) 100

1) 52.1

1) 79.8

1) 100

2) Palo (0.25) + DEX (8) on day 1 + DEX (8) on days 2–3

2) 149/149

  

2) 100

2) 51.2

2) 80.2

2) 100

Celio/2011 [11]

Multicenter, open-label, non-inferiority, parallel

1) Palo (0.25) + DEX (8) on day 1

1) 166/163

Breast, colon, lung

MEC (n = 237)c or AC

1) 62.0

1) 56.9

1) 60.8

1) 100

2) Palo (0.25) + DEX (8) on day 1 + DEX (8) on days 2–3

2) 166/161

  

2) 68.1

2) 57.2

2) 59.6

2) 100

Roila/2014 [13]

Multicenter, double-blind, superiority, parallel

`1) Palo (0.25) + APR (125) + DEX (8) on day 1 + APR (80) on days 2–3

1) 289/278

Breast

AC

1) 100

1) 53.1

1) 83.5

1) 100

2) Palo (0.25) + APR (125) + DEX (8) on day 1 + DEX (8) on days 2–3

2) 291/273

  

2) 99.3

2) 52.9

2) 76.9

2) 100

Furukawa/2015 [22]

Single-center, open-label, non-inferiority, parallel

1) Palo (0.75) + DEX (20) on day 1

1) 44/43

Ovary, endometrium, cervix

MEC (carboplatin)

1) 100

1) 59d

1) 90.7

1) 100

2) Palo (0.75) + DEX (20) on day 1 + DEX (8) on days 2–3

2) 44/39

  

2) 100

2) 62d

2) 92.3

2) 100

Matsuura/2015 [23]

Multicenter, open-label, superiority, parallel

1) Palo (0.75) + DEX (9.9 or 20) on day 1

1) 58/56

Ovary, endometrium, cervix

MEC (carboplatin)

1) 100

1) 57.7

1) 69.6

1) 100

2) Palo (0.75) + DEX (9.9 or 20) on day 1 + DEX (8) on days 2–3

2) 58/53

  

2) 100

2) 56.7

2) 64.2

2) 100

Komatsu/2015 [24]

Multicenter, open-label, non-inferiority, parallel

1) Palo (0.75) + DEX (9.9) on day 1

1) 154/151

NR

MEC (mainly oxaliplatin or irinotecan)

1) 43.0

1) 64.1

1) 51.0

1) 100

2) Palo (0.75) + DEX (9.9) on day 1 + DEX (8) on days 2–3

2) 154/154

  

2) 43.5

2) 64.0

2) 51.9

2) 100

Kosaka/2016 [25]

Single-center, single-blind, superiority, parallel

1) Palo (0.75) + DEX (12) + APR (125) on day 1 + APR (80) on days 2–3

1) 41/39

Breast

AC

1) 100

1) 52.6

1) 64.1

1) 100

2) Palo (0.75) + DEX (12) + APR (125) on day 1 + APR (80) + DEX (8) on days 2–3

2) 41/41

  

2) 100

2) 53.5

2) 61.0

2) 100

Ito/2018 [14]

Multicenter, double-blind, non-inferiority, parallel

1) Palo (0.75) + DEX (9.9) + NK-1RAf on day 1 + APR (80) on days 2–3

1) 200/200

Breast, oesophagus, stomach

AC (n = 306)e or cisplatin

1) 81.5

1) 54.1d

1) NR

1) 100

2) Palo (0.75) + DEX (9.9) + NK-1RA on day 1 + APR (80) + DEX (8) on days 2–3

2) 201/196

  

2) 80.1

2) 55d

2) NR

2) 100

  1. Abbreviations: Palo palonosetron, DEX dexamethasone, APR aprepitant, AC anthracycline plus cyclophosphamide, MEC moderately emetogenic chemotherapy, NK-1RA neurokinin-1 receptor antagonist, NR not reported
  2. apatients randomised/patients included in efficacy analyses
  3. bmain types of malignancies
  4. conly patients receiving chemotherapy regimens classified as MEC were analysed in the meta-analysis
  5. dmedian age
  6. eonly patients receiving AC-based regimens were analysed in the meta-analysis
  7. fpatients also received single-dose fosaprepitant on day 1 rather than aprepitant for 3 days
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us